Longevity signals.

The field's foundational map — twelve hallmarks now define what aging is and where intervention is possible.

Backed by Bezos and Yuri Milner with Nobel laureate Shinya Yamanaka — the largest private bet that aging is programmable.

Saudi-established and now among the world's largest geroscience funders — sovereign capital is entering longevity.

The Don't Die founder frames longevity as the next status frontier — and one that eventually democratizes.

From organ printing to genetics — antiaging research is now treated as a state-level priority.

Healthspan, not just lifespan — the consumer demand thesis behind the entire category.

Amimestrocel (瑞博生), derived from umbilical cord mesenchymal stem cells, received conditional approval in China in 2025 and is now entering a 2,000-person RCT for aging-related decline. The largest government-backed cellular rejuvenation trial to date.

A landmark 2023 Science paper showed taurine levels decline ~80% with age and that supplementation extended healthspan in mice and monkeys — triggering a wave of human trials. One of the most-cited longevity papers of the year.

The first senolytic to reach Phase 2 with positive data — proof that clearing senescent cells is clinically actionable. Validates the entire senolytic drug class that fisetin and quercetin are the supplement proxies for.

A 2,157-person RCT in adults 70+ found that the combination of omega-3, vitamin D, and exercise reduced biological aging (epigenetic clocks) by 3–4 months over 3 years. The largest longevity combination trial to date.

A 2023 placebo-controlled trial found calcium AKG reduced epigenetic (Horvath clock) biological age by a median of 8 years in older adults over 7 months — one of the most dramatic human longevity data points to date. Requires replication at scale.

The first randomized human trial of caloric restriction — 220 people, 2 years, 25% calorie reduction — showed significant slowing on DunedinPACE epigenetic aging clock. Proof that aging rate is modifiable by diet alone.

The Stanford neuroscientist's protocols — cold, heat, sleep, light — brought evidence-based longevity to a mass consumer audience. Largest distribution vector for longevity science outside mainstream media.

Our evidence library now covers 52 ingredients: Western molecules (rapamycin, NMN, AKG, sulforaphane) alongside Eastern tonic herbs (reishi, ashwagandha, baicalin, cordyceps) — each with real RCT counts, meta-analysis totals, and honest null results.

Clinique La Prairie (Switzerland) to Fountain Life (US) to Bioxcellerator (Colombia) — longevity clinics now charge $500–$500,000 per protocol. The market for evidence-backed clinical longevity is doubling every 3 years.

NMN reliably raises blood NAD+ in humans. Muscle, metabolic, and cognitive benefits appear in small trials. The TAME-adjacent question remains: does higher NAD+ slow human aging? Our evidence page shows every trial.

Randomized rapamycin trials in companion dogs — the largest mammalian longevity trial ever run — reported improved cardiac function and activity. Dogs as a model closes the gap between mice and humans.

A small but landmark Baylor RCT showed glycine + NAC supplementation in older adults corrected glutathione deficiency, mitochondrial dysfunction, oxidative stress, inflammation, insulin resistance, and physical decline simultaneously — more hallmarks addressed than any prior single-supplement trial.

A 2021 meta-analysis of 9 double-blind RCTs found KSM-66 ashwagandha significantly reduced cortisol, stress, and anxiety with no serious adverse events. One of the most reproducible adaptogen results in the literature.